Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 15

Modelling the Cost-Effectiveness of Indacaterol/Glycopyrronium versus Salmeterol/Fluticasone Using a Novel Markov Exacerbation-Based Approach

Authors Lakhotia B, Mahon R, Gutzwiller FS, Danyliv A, Nikolaev I, Thokala P

Received 24 January 2020

Accepted for publication 30 March 2020

Published 16 April 2020 Volume 2020:15 Pages 787—797

DOI https://doi.org/10.2147/COPD.S247156

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Dr Richard Russell


Bhavesh Lakhotia,1 Ronan Mahon,1 Florian S Gutzwiller,2 Andriy Danyliv,1 Ivan Nikolaev,2 Praveen Thokala3

1Novartis Ireland Limited, Dublin, Ireland; 2Novartis Pharma, Basel, AG, Switzerland; 3PT Health Economics Ltd, Sheffield, UK

Correspondence: Ronan Mahon
Team Head, Patient Access Services Product Lifecycle Services – Novartis Global Service Center Dublin, Vista Building, Elm Park Business Campus, Dublin 4, Ireland
Tel +353873647443
Email ronan.mahon@novartis.com

Purpose: Exacerbations drive outcomes and costs in chronic obstructive pulmonary disease (COPD). While patient-level (micro) simulation cost-effectiveness models have been developed that include exacerbations, such models are complex. We developed a novel, exacerbation-based model to assess the cost-effectiveness of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC) in COPD, using a Markov structure as a simplification of a previously validated microsimulation model.
Methods: The Markov model included three health states: infrequent or frequent exacerbator (IE or FE; ≤ 1 or ≥ 2 moderate/severe exacerbations in prior 12 months, respectively), or death. The model used data from the FLAME study and was run over a 10-year horizon. Cycle length was 1 year, after which patients remained in the same health state or transitioned to another. Analysis was conducted from a Swedish payer’s perspective (Swedish healthcare costs, converted into Euros), with incremental costs and quality-adjusted life-years (QALYs) calculated (discounted 3% annually).
Results: At all post-baseline timepoints, IND/GLY was associated with more patients in the IE health state and fewer patients in the FE and dead states relative to SFC. Over a 10-year period, IND/GLY was associated with a cost saving of € 1,887/patient, an incremental benefit of 0.142 QALYs, and an addition of 0.057 life-years, compared with SFC.
Conclusion: This Markov model represents a novel cost-effectiveness analysis for COPD, with simpler methodology than prior microsimulation models, while retaining exacerbations as drivers of disease progression. In patients with COPD with a history of exacerbations in the previous year, IND/GLY is a cost-effective treatment option compared with SFC.

Keywords: chronic obstructive pulmonary disease, indacaterol/glycopyrronium, cost-effective, exacerbation, Markov model


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]